The following article is part of conference coverage from the 2018 American Academy of Dermatology Annual Meeting in San Diego, California. Dermatology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in dermatology. Check back for the latest news from AAD 2018.

ASN002, a novel oral JAK and SYK inhibitor, is well-tolerated and effective for the treatment of moderate to severe atopic dermatitis (AD). Results of the preliminary double-blind, placebo-controlled trial (ClinicalTrials.gov Identifier: NCT03139981) were presented at the 2018 American Academy of Dermatology Annual Meeting, February 16-20, 2018 in San Diego, California.

Researchers led by Robert Bissonnette, MD, MSc, FRCPC, of Innovaderm Research in Montreal, Canada randomly assigned patients with AD (n=36) to receive 20 mg, 40 mg, or 80 mg of ASN002 or placebo once daily for 4 weeks.

Participants had an Eczema Area and Severity Index (EASI) score ≥16, body surface area (BSA) involvement ≥10%, and an Investigator’s Global Assessment (IGA) of ≥3 at baseline. Use of concomitant topical corticosteroids or other immunosuppressants was not permitted during or prior to the study.

Overall, ASN002 was well-tolerated at all doses, with the most common adverse events being mild headache and nausea, most of which were transient and occurred on day 1 of dosing. Dose-related declines in EASI50 (30%-82%) and EASI75 (10%-55%) were seen after 4 weeks, with an average decrease in EASI of 28%-68% and 19%-51% in Itch Numeric Rating Scale score. Mid- and high-dose groups also saw improvements in BSA and IGA assessments.

Overall, the investigators reported robust improvements in EASI and pruritis at 4 weeks in patients with moderate to severe AD, suggesting that ASN002 is both safe and effective.

For more coverage of AAD 2018, click here.

Related Articles

Reference

Bissonnette R, et al. Efficacy and safety of oral ASN002, a novel JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled clinical study. Presented at: 2018 American Academy of Dermatology Annual Meeting. February 16-20, 2018; San Diego, CA. Abstract 6777.